INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 78 filers reported holding INTELLIA THERAPEUTICS INC in Q1 2017. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $118,035,089 | -17.1% | 3,732,925 | +6.9% | 0.01% | 0.0% |
Q2 2023 | $142,436,017 | +8.0% | 3,492,791 | -1.3% | 0.01% | 0.0% |
Q1 2023 | $131,921,786 | -49.6% | 3,539,638 | -52.9% | 0.01% | -12.5% |
Q4 2022 | $262,006,036 | +74.2% | 7,509,488 | +179.4% | 0.01% | -20.0% |
Q3 2022 | $150,405,000 | -7.6% | 2,687,719 | -14.5% | 0.01% | 0.0% |
Q2 2022 | $162,724,000 | -6.6% | 3,143,811 | +31.1% | 0.01% | +11.1% |
Q1 2022 | $174,228,000 | -20.0% | 2,397,527 | +30.2% | 0.01% | -10.0% |
Q4 2021 | $217,733,000 | -2.3% | 1,841,451 | +10.8% | 0.01% | -16.7% |
Q3 2021 | $222,921,000 | -22.6% | 1,661,730 | -6.6% | 0.01% | -20.0% |
Q2 2021 | $287,931,000 | +96.2% | 1,778,342 | -2.8% | 0.02% | +87.5% |
Q1 2021 | $146,757,000 | +20.3% | 1,828,639 | -18.5% | 0.01% | +14.3% |
Q4 2020 | $122,005,000 | +100.6% | 2,242,740 | -26.7% | 0.01% | +75.0% |
Q3 2020 | $60,805,000 | +24.7% | 3,058,598 | +31.9% | 0.00% | 0.0% |
Q2 2020 | $48,751,000 | +131.1% | 2,319,288 | +34.5% | 0.00% | +100.0% |
Q1 2020 | $21,093,000 | -15.1% | 1,724,683 | +1.8% | 0.00% | 0.0% |
Q4 2019 | $24,843,000 | +1.9% | 1,693,469 | -7.3% | 0.00% | 0.0% |
Q3 2019 | $24,381,000 | -19.4% | 1,826,317 | -1.2% | 0.00% | 0.0% |
Q2 2019 | $30,256,000 | -0.4% | 1,848,280 | +4.0% | 0.00% | 0.0% |
Q1 2019 | $30,365,000 | -3.9% | 1,777,835 | -23.2% | 0.00% | -33.3% |
Q4 2018 | $31,592,000 | -46.6% | 2,314,430 | +12.0% | 0.00% | -40.0% |
Q3 2018 | $59,155,000 | -19.8% | 2,067,097 | -23.3% | 0.01% | -16.7% |
Q2 2018 | $73,774,000 | +126.9% | 2,696,421 | +74.9% | 0.01% | +100.0% |
Q1 2018 | $32,514,000 | +46.5% | 1,541,612 | +33.5% | 0.00% | +50.0% |
Q4 2017 | $22,199,000 | +371.5% | 1,155,070 | +509.9% | 0.00% | – |
Q3 2017 | $4,708,000 | +78.5% | 189,385 | +14.9% | 0.00% | – |
Q2 2017 | $2,638,000 | +72.8% | 164,798 | +52.0% | 0.00% | – |
Q1 2017 | $1,527,000 | +26.1% | 108,435 | +17.4% | 0.00% | – |
Q4 2016 | $1,211,000 | -24.7% | 92,355 | -2.4% | 0.00% | – |
Q3 2016 | $1,608,000 | +6.3% | 94,580 | +33.4% | 0.00% | – |
Q2 2016 | $1,513,000 | – | 70,874 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 744,160 | $54,078,000 | 5.79% |
Discovery Value Fund | 986,173 | $71,665,000 | 5.28% |
Ally Bridge Group (NY) LLC | 60,000 | $4,360,000 | 3.23% |
MPM BioImpact LLC | 159,409 | $11,584,000 | 3.11% |
ARK Investment Management | 8,981,029 | $652,651,000 | 2.72% |
Elmwood Wealth Management, Inc. | 67,599 | $4,912,000 | 2.52% |
Nikko Asset Management Americas, Inc. | 2,872,269 | $192,442,000 | 1.41% |
Frazier Life Sciences Management, L.P. | 203,684 | $14,802,000 | 1.26% |
REGENTS OF THE UNIVERSITY OF CALIFORNIA | 111,440 | $8,098,000 | 1.22% |
Merlin Capital, Inc | 11,575 | $841,000 | 1.11% |